Cardiac manifestations in children with the multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection: Systematic review and meta-analysis

dc.creatorArantes Junior, Márcio Antônio Ferreira
dc.creatorConegundes, Ana Flávia
dc.creatorMiranda, Bárbara Castello Branco
dc.creatorCampos, Alexia Stenner Rodrigues Radicchi
dc.creatorVieira, Ana Luiza França
dc.creatorFaleiro, Matheus Daniel
dc.creatorCampos, Marco Antônio
dc.creatorKroon, Erna Geessien
dc.creatorBentes, Aline Almeida
dc.date2023-03-14T18:11:31Z
dc.date2023-03-14T18:11:31Z
dc.date2023
dc.date.accessioned2023-09-26T20:14:26Z
dc.date.available2023-09-26T20:14:26Z
dc.identifierARANTES JUNIOR, Márcio Antonio Ferreira et al. Cardiac manifestations in children with the multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection: Systematic review and meta-analysis. Rev Med Virol, e2432, 2023. doi: 10.1002/rmv.2432.
dc.identifier1052-9276
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/57367
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8852203
dc.descriptionAccording to the World Health Organisation, as of October 2022, there have been 55,560,329 reported cases of SARS-COV-2 in patients under 19 years old. It is estimated that about 0.06% of these patients may develop MIS-C, representing more than 2 million children worldwide. This systematic review and meta-analysis examined the pooled prevalence of cardiovascular manifestation and cardiac complications in children hospitalised with MIS-C. The PROSPERO register number is CRD42022327212. We included case-report studies, case-control studies, cohort studies, and cross-sectional studies, as well as clinical trials or studies describing cardiac manifestations of MIS-C and its sequelae in a paediatric population. Initially, 285 studies were selected, but there were 154 duplicates, and 81 were excluded because they did not fit the eligibility criteria. Thus, 50 studies were selected for review, and 30 were included in the meta-analysis. A total sample size of 1445 children was included. The combined prevalence of myocarditis or pericarditis was 34.3% (95% CI: 25.0%-44.2%). The combined prevalence for echocardiogram anomalies was 40.8% (95% CI: 30.5%-51.5%), that of Kawasaki disease presentation was 14.8% (95% CI: 7.5%-23.7%), and that of coronary dilation was 15.2% (95% CI: 11.0%-19.8%). The rate of electrocardiogram anomalies was 5.3% (95% CI: 0.8%-12.3%), and the mortality rate was 0.5% (CI 95%: 0%-1.2%). Furthermore, 186 children still had complications at discharge, with a combined prevalence of such long-lasting manifestations of 9.3% (95% CI: 5.6%-13.7%). Studies that assess whether these children will have an increased cardiovascular risk with a greater chance of acute myocardial infarction, arrhythmias, or thrombosis will be essential for healthcare planning.
dc.description2099-12-31
dc.formatapplication/pdf
dc.languageeng
dc.publisherWiley
dc.rightsrestricted access
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectcardiac complications
dc.subjectcardiac complications
dc.subjectchildren; multisystem
dc.subjectinflammatory syndrome in children
dc.titleCardiac manifestations in children with the multisystem inflammatory syndrome (MIS-C) associated with SARS-CoV-2 infection: Systematic review and meta-analysis
dc.typeArticle


Este ítem pertenece a la siguiente institución